210.9500 -3.40 (-1.59%)
NSE Aug 08, 2025 15:31 PM
Volume: 825.0K
 

Marksans Pharma

Centrum Broking
Source: Bloomberg, Centrum Research, *as on 8th June 2018 Recommendation and key risks: We have revised our FY19E and FY20E EPS downwards by 41% and 43% respectively. We downgrade MPL to Hold from Buy rating, with a TP of Rs31 based on 18x March'20E EPS of Rs1.7, and a 10.2%% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA...
Marksans Pharma Ltd. has lost -22.71% in the last 6 Months
More from Marksans Pharma Ltd.
Recommended